Insmed gains US approval of lung disease drug forecast to be blockbuster
Written by
BioPharma Dive
Published
0
comments
0
min
Brinsupri, which Insmed acquired from AstraZeneca nearly a decade ago, is the first treatment for bronchiectasis that’s not caused by cystic fibrosis.